Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

bination with docetaxel retreatment have indicated that OGX-011 may help restore tumor sensitivity to docetaxel and may improve overall survival for second-line therapy."

The planned initiation of this Phase 3 trial is supported by encouraging preliminary Phase 2 data that were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO). These preliminary data are derived from a Phase 2 study evaluating 42 patients with HRPC who had received first-line docetaxel therapy and required second-line chemotherapy: 22 patients were treated with mitoxantrone plus OGX-011 and 20 patients with docetaxel retreatment plus OGX-011. While follow up on surviving patients is still ongoing, the following preliminary findings were reported:

- Survival continued to be better than expected based on previously

published reports: With a median follow-up of 17.2 months following the

start of second-line chemotherapy, median survival has been estimated

at 11.4 months in the mitoxantrone plus OGX-011 group and 14.7 months

in the docetaxel retreatment plus OGX-011 group. These data compare

favorably with published results reporting median survivals at

approximately 10 months for HRPC patients receiving second-line

chemotherapy without OGX-011.

- In addition, average serum clusterin levels during treatment were

predictive of survival, with low-average levels predicting median

survival time of 14.7 months compared to high-average levels predicting

median survival time of 5.5 months. These data suggest that a reduction

in clusterin levels may improve survival.

About OGX-011

OGX-011 is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer indications and in response to many cancer treatments. Increased clusterin production is observed in many human cancers, including prostate, non-small c
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... is being held on October 29-30 in San Francisco, ... industry, academic and government researchers and clinicians focused on ... space. , In the twelve years since the ... therapies have been introduced with pharmacogenetic information in the ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... the most promising biotech start-up company at the recent ... a proprietary process to convert wastewater from food and ... was given top honors out of 22 total entries ... from the sponsoring Colorado law firm of Dorsey & ...
... 8 Prosolia, Inc. introduces a new,advanced Omni Spray Ion ... Omni Spray 2-D Ion Source has an automated,surface platform which ... up to 76 mm by 114 mm, which is the ... The Omni Spray 2-D Ion Source ...
... leader in,workforce and recruitment solutions announced today that it ... company with its prestigious 2008,Supplier of Excellence Award. ... suppliers, this is the first time they have ever ... are thousands of suppliers of,products and services to Alcon ...
Cached Biology Technology:Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 2Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 3Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 4Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 5Prosolia to Introduce Omni Spray(R) Ion Source in 2-D Format 2Adecco Receives Honor From Alcon Laboratories 2
(Date:8/20/2014)... 4,000 members, it triggers an important first stage in ... of comb used for rearing male reproductive, called drones. ... and Behaviour at Cornell University, led by Michael Smith, ... The results are published in Springer,s journal Naturwissenschaften ... isn,t always a honeybee colony,s top priority. Early ...
(Date:8/20/2014)... -- The second annual Biometrics UnPlugged Executive Summit, set ... on September 15, 2014, will feature ... Strategy at Samsung, and Philippe de Raet, Vice President, ... year,s event is Mobility at the Crossroads of ... Mobility at the Crossroads of Commerce & Privacy ...
(Date:8/19/2014)... Wind and ... amount of electricity is to be produced with renewable energy ... stored during productive periods so that these fluctuations can be ... for the purpose. Science and industry are therefore working on ... that used to be too expensive or unsophisticated to be ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... Xanex or Xanax? Or maybe Zantac? If you're a health ... , An estimated 1.3 million people in the United States ... U.S. Federal Drug Administration (FDA) has been working to reduce ... in which a patient needed an injection of Narcan but ...
... Genes & Development, Dr. Mary Ellen Perry and colleagues ... for cancer therapies. , The p53 tumor suppressor plays ... strategies aim to activate p53 in order to curb ... and therefore an attractive target to modulate p53 activity ...
... death by suicide generally decreases in the weeks after ... study led by Group Health Cooperative researchers and published ... Psychiatry. The study also found that the risk of ... less than the risk posed by older medications. ...
Cached Biology News:Computer scientist sorts out confusable drug names 2Suicide risk does not increase when adults start using antidepressants, study finds 2
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
GOAT ANTI HUMAN FACTOR 8RELATED ANTIGEN...
ANTI CORTIS BIN GLOB...
Biology Products: